Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC

Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC: Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.